AlloVir, Inc. (NASDAQ:ALVR) insider Beek Jeroen B. Van sold 5,916 shares of the business’s stock in a transaction dated Friday, September 17th. The stock was sold at an average price of $25.08, for a total transaction of $148,373.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
AlloVir stock traded down $1.01 during midday trading on Monday, hitting $22.98. The company’s stock had a trading volume of 315,977 shares, compared to its average volume of 292,994. AlloVir, Inc. has a 1-year low of $16.66 and a 1-year high of $48.96. The company has a 50-day moving average price of $19.57 and a two-hundred day moving average price of $21.92. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -8.87 and a beta of 3.35.
AlloVir (NASDAQ:ALVR) last released its earnings results on Thursday, August 5th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.14). As a group, equities research analysts forecast that AlloVir, Inc. will post -1.99 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of AlloVir during the 1st quarter valued at $32,000. Great West Life Assurance Co. Can grew its stake in shares of AlloVir by 115.0% in the 2nd quarter. Great West Life Assurance Co. Can now owns 1,972 shares of the company’s stock worth $39,000 after acquiring an additional 1,055 shares in the last quarter. Royal Bank of Canada grew its stake in shares of AlloVir by 260.6% in the 1st quarter. Royal Bank of Canada now owns 2,362 shares of the company’s stock worth $56,000 after acquiring an additional 1,707 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in AlloVir during the first quarter valued at about $73,000. Finally, Legal & General Group Plc grew its position in AlloVir by 41.5% during the second quarter. Legal & General Group Plc now owns 5,429 shares of the company’s stock valued at $107,000 after buying an additional 1,591 shares during the period. 40.54% of the stock is currently owned by hedge funds and other institutional investors.
AlloVir Company Profile
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Recommended Story: VIX – Volatility Index
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.